Key updates to this guideline include: ➡️ The use of the American Heart Association PREVENT-ASCVD equations to guide primary-prevention and lipid-lowering therapy decisions. ➡️ Testing Lp(a) at least once in a lifetime and selective apolipoprotein B measurement to improve risk

Want to know my most important takeaways from the new 2026 Cholesterol Guidelines? Set to music, of course. AHA Science American College of Cardiology ASPC Clip here- Full song at the link- youtube.com/watch?v=DRO5kH…

Oral #enlicitide lowered LDL-C, #ApoB, & non-HDL-C more than oral non-statin comparators at day 56 in statin-treated adults with a history of a major #ASCVD event or at increased risk for a first event. jacc.org/doi/10.1016/j.… #ACC26 #JACC #PCSK9i

Our latest video in our partnership with Dr. Glaucomflecken summarizes the CORALreef Lipids trial, which assessed the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels over a 52-week period. Read the full study for free: nej.md/DrG37